Conditions: Ankylosing Spondylitis
Keywords: Ankylosing spondylitis AS ASAS inflammatory back pain
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 371
Healthy volunteers: no

Brief summary:
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.

Detailed description:

Arms:
arm 1: Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study. arm 2: Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study. arm 3: Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.

Interventions: intervention 1: Secukinumab (75 mg) intervention 2: Secukinumab (150 mg) intervention 3: Placebo
Intervention descriptions: intervention 1: Secukinumab (75 mg) intervention 2: Secukinumab (150 mg) intervention 3: Placebo

Protocol document: